TrialEuropean urology2024

A Randomized, Open-label, Cross-over Phase 2 Trial of Darolutamide and Enzalutamide in Men with Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer: Patient Preference and Cognitive Function in ODENZA.

Emeline Colomba et al.PubMed ↗Publisher ↗

No numbers read from the abstract.